Drug use evaluation of antidyslipidemic agents at a community hospital in Japan

Medicine & Life Sciences

• Drug Evaluation 67%
• Community Hospital 60%
• Dyslipidemias 53%
• Coronary Disease 48%
• Japan 44%
• Drug Therapy 21%
• Guidelines 17%
• Lipids 11%
• Medical Staff 10%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 8%
• Serum 8%
• LDL Cholesterol 8%
• Pharmaceutical Preparations 7%
• Outpatients 6%
• Smoking 6%
• Obesity 6%
• Therapeutics 5%
• Physicians 5%
• Phenotype 5%

Chemical Compounds

• Antidyslipidemic 100%
• Low-Density Lipoprotein Cholesterol 43%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 39%
• Lipid 37%
• Drug 28%